Details

Autor(en) / Beteiligte

• Didier, Romain
• Eltchaninoff, Hélène
• Donzeau-Gouge, Patrick
• Chevreul, Karine
• Fajadet, Jean
• Leprince, Pascal
• Leguerrier, Alain
• Lièvre, Michel
• Prat, Alain
• Teiger, Emmanuel
• Lefevre, Thierry
• Tchetché, Didier
• Carrié, Didier
• Himbert, Dominique
• Albat, Bernard
• Cribier, Alain
• Sudre, Arnaud
• Blanchard, Didier
• Rioufol, Gilles
• Collet, Frederic
• Houel, Remi
• Dos Santos, Pierre
• Meneveau, Nicolas
• Ghostine, Said
• Manigold, Thibaut
• Guyon, Philippe
• Cuisset, Thomas
• Le Breton, Herve
• Delepine, Stephane
• Favereau, Xavier
• Souteyrand, Geraud
• Ohlmann, Patrick
• Doisy, Vincent
• Lognoné, Thérèse
• Gommeaux, Antoine
• Claudel, Jean-Philippe
• Bourlon, Francois
• Bertrand, Bernard
• Iung, Bernard
• Gilard, Martine

Titel

Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients: FRANCE-2 Registry

Ist Teil von

• Circulation (New York, N.Y.), 2018-12, Vol.138 (23), p.2597-2607

Ort / Verlag

by the American College of Cardiology Foundation and the American Heart Association, Inc

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• BACKGROUND:The FRANCE-2 registry (French Aortic National Corevalve and Edwards) previously reported good early- and medium-term clinical and echocardiographic efficacy for transcatheter aortic valve replacement. We here report 5-year follow-up results from the registry. METHODS:The registry includes all consecutive patients undergoing transcatheter aortic valve replacement for severe aortic stenosis in France. Follow-up is scheduled at 30 days, 6 months, then annually from 1 to 5 years. Clinical events were defined according to the Valve Academic Research Consortium criteria, and hemodynamic structural valve deterioration (SVD) was defined according to the consensus statement by the European Association of Percutaneous Cardiovascular Interventions. RESULTS:Between January 2010 and January 2012, 4201 patients were enrolled in 34 centers. Five-year vital status was available for 95.5% of patients; 88.1% had clinical evaluation or died. Overall, at 5 years, all-cause mortality was 60.8% (n=2478; 95% CI, 59.3% to 62.3%). The majority of cardiovascular events occurred in the first month after valve implantation, and incidence remained low thereafter, at <2% per year up to 5 years, except for heart failure. The rate of heart failure was 14.3% at 1 year, then decreased over time to <5% per year. In cumulative incidence function, the rates of severe SVD and moderate/severe SVD at 5 years were 2.5% and 13.3%, respectively. Mortality did not differ between patients with or without severe SVD (hazard ratio, 0.71; 95% CI, 0.47–1.07; P=0.1). Finally, in the population of patients with severe SVD, 1 patient (1.7%) experienced a stroke, and 8 patients presented ≥1 heart failure event (13.3%). CONCLUSIONS:The 5-year follow-up results of the FRANCE-2 registry represent the largest long-term data set available in a high-risk population. In surviving patients, the low rate of clinical events and the low level of SVD after 1 year support the long-term efficacy of transcatheter aortic valve replacement in both types of transcatheter prosthesis featuring in the registry.